Floatz logo

Pirfenidone

Acute Lung Injury

Fujian Medical University Union HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Acute Lung Injury cohort.

Asset / SponsorPhaseRating
Fibrinogen Concentrate Human
IRCCS Policlinico S. Donato
Phase 2CCC
Prothrombin Complex Concentrate, Human
IRCCS Policlinico S. Donato
Phase 2CCC
Fresh Frozen Plasma
IRCCS Policlinico S. Donato
Phase 2CCC
Bxcl501
The Second Affiliated Hospital of Chongqing Medical University
N/ANR

Same molecule, other indications

Pirfenidone is also rated in:

idiopathic pulmonary fibrosisDormant
A
Indicative ·
80 / 100
View asset →
pulmonary fibrosisDormant
BB
Indicative ·
66 / 100
View asset →
fibrotic liver diseaseDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →